Study	Reason for exclusion
Angelucci 2012	Study not randomised, not controlled. Prospective, 1‐year, multi‐centre, single‐arm trial including 152 lower risk and transfusion dependent MDS patients.
Brosnahan 2008	Case report of MDS patient with acute interstitial nephritis.
Cermak 2013	Study not randomised. Comparative study on 48 patients receiving deferiprone (January 2006 to July 2007) and 65 patients receiving deferasirox (January 2008 to August 2010).
Di Tucci 2007	Case report of patient with primary myelofibrosis (PMF).
Fox 2009	Study not randomised. Matched‐pair analysis on 186 MDS patients.
García‐Delgado 2009	Study not randomised, not controlled. Single‐arm study evaluating the effect of deferasirox on oxidative stress and vascular dysfunction in MDS patients with iron overload (4 people with MDS).
Gattermann 2007, EPIC	Study not randomised, not controlled. Prospective, 1‐year, multi‐centre, single‐arm, open‐label phase IIIB/IV trial (1744 people with various transfusion‐dependent anaemias including 341 people with MDS and 116 with AA).
Gattermann 2009	Study not randomised, not controlled. Prospective, multi‐centre, post‐marketing, single‐arm study on 123 chelation‐naive (Extend) and 44 pre‐chelated (Exjange) MDS patients.
Ghoti 2009	Study not randomised, not controlled. Single‐arm study evaluating decrease in intra‐ and extra‐cellular free iron species and oxidative stress parameters during treatment with deferasirox in iron‐loaded patients with MDS.
Greenberg 2006, US2 study	Study not randomised, not controlled. Prospective, phase II, multi‐centre, single‐arm study on 30 people with MDS.
Leitch 2007	Study not randomised, not controlled. Retrospective analysis of 41 people with PMF.
Leitch 2009	Case report.
List 2006, US3 study	Study not randomised, not controlled. Prospective, phase II, open‐label, single‐arm study on 176 people with MDS.
Messa 2008	Retrospective case series of 7 people with MDS and 3 people with PMF.
Metzgeroth 2009	Study not randomised, not controlled. Prospective, phase II, open‐label, single‐arm, single‐centre study of 12 people with MDS.
Min 2008	Study not randomised, not controlled. Prospective, multi‐centre, open‐label, single‐arm study of 29 people with MDS and 50 people with AA.
Miyazawa 2006	Study not randomised, not controlled. Prospective, phase I, open‐label, multi‐centre, dose‐escalation study on 26 people with MDS or AA.
Nolte 2013	Study not randomised, not controlled. Open label, 1‐year, single‐arm, multi‐centre trial on 50 patients with low and intermediate‐1 risk MDS and transfusional iron overload.
Peng 2013	Study on patients with thalassemia (Chinese full text not available; assessment based on English abstract and references).
Pennell 2014, CORDELIA	Study planned to include MDS patients; however, of the four screened patients with MDS, none fulfilled the inclusion criteria.
Porter 2004	Study not randomised, not controlled. Prospective, phase II, single‐arm study of 184 people with transfusion‐dependent anaemia including 47 people with MDS.
Rachmilewitz 2008	Study not randomised, not controlled. Prospective, single‐arm study of 15 people with MDS.
Remacha 2010	Study not randomised, not controlled. Cross‐sectional study on 549 MDS patients.
Rose 2007	Study not randomised, not controlled. Survey of 170 people with MDS from 18 French GFM centres.
Wimazal 2009	Case series of 14 MDS patients treated with deferasirox (500 to 1500 mg/day) for up to 24 months.

Only reports on observational studies or case series are mentioned in this table.

AA ‐ aplastic anaemia;

GFM ‐ Groupe Francophone des Myelodysplasies;

MDS ‐ myelodysplastic syndrome;

PMF ‐ primary myelofibrosis.